Galcanezumab

Drug Profile

Galcanezumab

Alternative Names: LY2951742

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cluster headache; Migraine
  • Discontinued Musculoskeletal pain

Most Recent Events

  • 12 May 2017 Eli Lilly announces intention to submit BLA to US-FDA for Migraine (Prevention) in the second half of 2017, followed by submissions to other regulatory agencies around the world.
  • 12 May 2017 Efficacy and adverse events data from three phase III trials, EVOLVE-1, EVOLVE-2 and REGAIN in Migrain released by Eli Lilly
  • 22 Apr 2017 Pooled adverse events data from three phase II trials in Migraine (Prevention) presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top